Onco Actu du 28 août 2015

	3.1 Tabac
FDA takes action against three tobacco manufacturers for making “additive-free” and/or “natural” claims on cigarette labeling [FDA] The action marks the first time the FDA has used its authority under the Family Smoking Prevention and Tobacco Control Act of 2009 to pursue regulatory action regarding the use of “additive-free” or “natural” claims on tobacco product labeling.
E-cigarette ‘safety’ study was written by industry funded scientists, Lancet warns [The Telegraph] Public Health England claimed e-cigarettes were safe but relied on evidence provided by scientists funded by the vaping industry.
Bill to regulate e-cigarettes clears California legislative hurdle [Reuters] The e-cigarette regulations, introduced by State Senator Mark Leno, a Democrat from San Francisco, would ban use of the devices, also known as vapor cigarettes or vapes, in the workplace, at schools and other places where cigarettes already are forbidden, and would require that they be sold in child-resistant packaging.
	4. Dépistage, diagnostic et pronostic
2015-2019 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence [ReportsnReports] Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
	4.12 Biopsies liquides
MicroRNA Panel Shows Early Potential as Biomarker of Pancreatic Precancers [AACR] “Our study shows that new, relatively inexpensive digital technology could reliably measure miRNAs in blood plasma from individuals newly diagnosed with pancreatic cancer precursors called IPMNs, and healthy individuals.”
More evidence that blood samples could help monitor breast cancer [Cancer Research UK] But such a test is a long way off, according to Professor Jacqui Shaw, an expert in circulating tumour DNA from Cancer Research UK, which part-funded the study.
	4.9 Dép., diag. & prono. - Sein
Genetic Test Impacts Chemo Choices In Surprising Ways [TIME] “The Oncotype DX test is impacting the receipt of chemotherapy, but the impact isn’t in one direction or another in terms of whether people are more or less likely to get chemotherapy.”
	5. Traitements
Can a Modified Poliovirus Fight Advanced Prostate Cancer Too? [Duke] PVSRIPO has been modified and tamed with the addition of a rhinovirus, the virus responsible for the common cold. The engineered virus specifically targets and destroys tumor cells while leaving healthy cells unscathed.
Everything You Need to Know About Precision Medicine [Popular Science] “We need to marry the information about the genetics of tumors with our understanding about their basic function in order to make real breakthroughs in individual patients.”
Let Fear Guide Early Stage Breast-Cancer Decisions [NY Times] The most misleading suggestion from the media coverage would be that the study establishes the safety of not getting treatment. It does not.
	5.10 Traitements - Essais
Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients [Johnson & Johnson] Study results also showed 65 percent of responding patients remained in remission at 12 months.
	5.2.1 Pharma - Partenariats
Syndax, Genentech Launch Cancer Immunotherapy Trial Collaboration [GEN] The Phase Ib/II trial will be designed to assess the safety, tolerability, and preliminary efficacy of Syndax' entinostat in combination with Genentech's atezolizumab (MPDL3280A) in patients with triple-negative breast cancer. Syndax has agreed to conduct the trial.
	5.4 Traitements - Economie
Eli Lilly's marginal cancer drug becomes Exhibit A in pricing debate [FierceBiotech] Using what they called a "highly sophisticated" pricing model, researchers at Winship Cancer Institute of Emory University and Georgia Institute of Technology say they considered the benefits and the drawbacks and came up with a fair market value of $563 to $1,309 per three-week cycle for necitumumab--just a fraction of the six-figure annual prices that even the most marginal cancer drugs like this can fetch.
	6.10 Politiques
Cancer, transplant patients protest over Venezuela's medicine shortages [Reuters] Venezuelans with chronic medical conditions such as breast cancer, hemophilia and transplants protested in Caracas on Thursday, the latest demonstration to demand urgent medicines in a country beset with shortages.
	6.11 Patients
Living With Cancer: Collateral Damage [NY Times] Sexual dysfunction and incontinence in prostate cancer survivors underscore a quandary that shadows oncology. As we all realize, procedures that prolong lives also impair them. Yet cancer patients who must forfeit quality of life to gain quantity of life rarely receive adequate warning before treatment or guidance afterward.
	6.8 Communication
To improve radiotherapy for patients, we need to improve its profile [Cancer Research UK] The Radiotherapy Awareness Programme (RAP, which I chair) recently launched a survey to find out just how much people in the UK did know about the newer forms of radiotherapy. And we were surprised to see that the answer was “not much”.